|
1
|
Damber JE and Aus G: Prostate cancer.
Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burton AJ, Tilling KM, Holly JM, Hamdy FC,
Rowlands MA, Donovan JL and Martin RM: Metabolic imbalance and
prostate cancer progression. Int J Mol Epidemiol Genet. 1:248–271.
2010.PubMed/NCBI
|
|
3
|
Di Lorenzo G and De Placido S: Hormone
refractory prostate cancer (HRPC): present and future approaches of
therapy. Int J Immunopathol Pharmacol. 19:11–34. 2006.PubMed/NCBI
|
|
4
|
Dash R, Azab B, Shen XN, Sokhi UK, Sarkar
S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT,
Grant S, Sarkar D and Fisher PB: Developing an effective gene
therapy for prostate cancer: new technologies with potential to
translate from the laboratory into the clinic. Discov Med.
11:46–56. 2011.PubMed/NCBI
|
|
5
|
Hu W and Kavanagh JJ: Anticancer therapy
targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Danen-Van Oorschot AA, Zhang YH, Leliveld
SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams
JP, Mumberg D and Noteborn MH: Importance of nuclear localization
of apoptin for tumor-specific induction of apoptosis. J Biol Chem.
278:27729–27736. 2003.PubMed/NCBI
|
|
7
|
Oro C and Jans DA: The tumour specific
pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr
Drug Targets. 5:179–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Poon IK, Oro C, Dias MM, Zhang J and Jans
DA: Apoptin nuclear accumulation is modulated by a CRM1-recognized
nuclear export signal that is active in normal but not in tumor
cells. Cancer Res. 65:7059–7064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Jin N, Mi Z, Lian H, Sun L and Zheng
H: Antitumor effects of a recombinant fowlpox virus expressing
Apoptin in vivo and in vitro. Int J Cancer. 119:2948–2957. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maioli E, Torricelli C, Fortino V,
Carlucci F, Tommassini V and Pacini A: Critical appraisal of the
MTT assay in the presence of rottlerin and uncouplers. Biol Proced
Online. 11:227–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitrovic T, Stamenkovic S, Cvetkovic V,
Tosic S, Stankovic M, Radojevic I, Stefanovic O, Comic L, Dacic D,
Curcic M and Markovic S: Antioxidant, antimicrobial and
antiproliferative activities of five lichen species. Int J Mol Sci.
12:5428–5448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baskic D, Popovic S, Ristic P and
Arsenijevic NN: Analysis of cycloheximide-induced apoptosis in
human leukocytes: fluorescence microscopy using Annexin V/propidium
iodide versus acridin orange/ethidium bromide. Cell Biol Int.
30:924–932. 2006. View Article : Google Scholar
|
|
13
|
Ding W, Ju S, Jiang S, Zhu L, Wang Y and
Wang H: Reduced APRIL expression induces cellular senescence via a
HSPG-dependent pathway. Pathol Oncol Res. 15:693–701. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Candal E, Anadon R, DeGrip WJ and
Rodriguez-Moldes I: Patterns of cell proliferation and cell death
in the developing retina and optic tectum of the brown trout. Brain
Res Dev Brain Res. 154:101–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panigrahi S, Stetefeld J, Jangamreddy JR,
Mandal S, Mandal SK and Los M: Modeling of molecular interaction
between apoptin, BCR-Abl and CrkL - an alternative approach to
conventional rational drug design. PLoS One. 7:e283952012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adair BM: Immunopathogenesis of chicken
anemia virus infection. Dev Comp Immunol. 24:247–255. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Los M, Panigrahi S, Rashedi I, Mandal S,
Stetefeld J, Essmann F and Schulze-Osthoff K: Apoptin, a
tumor-selective killer. Biochim Biophys Acta. 1793:1335–1342. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van der Eb MM, Pietersen AM, Speetjens FM,
Kuppen PJ, van de Velde CJ, Noteborn MH and Hoeben RC: Gene therapy
with apoptin induces regression of xenografted human hepatomas.
Cancer Gene Ther. 9:53–61. 2002.PubMed/NCBI
|
|
19
|
Olijslagers S, Dege AY, Dinsart C,
Voorhoeve M, Rommelaere J, Noteborn MH and Cornelis JJ:
Potentiation of a recombinant oncolytic parvovirus by expression of
Apoptin. Cancer Gene Ther. 8:958–965. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pietersen AM, van der Eb MM, Rademaker HJ,
van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, van Dierendonck JH,
van Ormondt H, Masman D, van de Velde CJ, van der Eb AJ, Hoeben RC
and Noteborn MH: Specific tumor-cell killing with adenovirus
vectors containing the apoptin gene. Gene Ther. 6:882–892. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heilman DW, Teodoro JG and Green MR:
Apoptin nucleocytoplasmic shuttling is required for cell
type-specific localization, apoptosis, and recruitment of the
anaphase-promoting complex/cyclosome to PML bodies. J Virol.
80:7535–7545. 2006. View Article : Google Scholar
|
|
22
|
Maddika S, Booy EP, Johar D, Gibson SB,
Ghavami S and Los M: Cancer-specific toxicity of apoptin is
independent of death receptors but involves the loss of
mitochondrial membrane potential and the release of mitochondrial
cell-death mediators by a Nur77-dependent pathway. J Cell Sci.
118:4485–4493. 2005. View Article : Google Scholar
|
|
23
|
Maddika S, Mendoza FJ, Hauff K, Zamzow CR,
Paranjothy T and Los M: Cancer-selective therapy of the future:
apoptin and its mechanism of action. Cancer Biol Ther. 5:10–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maddika S, Wiechec E, Ande SR, Poon IK,
Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K and Los M:
Interaction with PI3-kinase contributes to the cytotoxic activity
of apoptin. Oncogene. 27:3060–3065. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wagstaff KM and Jans DA: Nuclear drug
delivery to target tumour cells. Eur J Pharmacol. 625:174–180.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang J, Cole D, Westwood N, Macpherson L,
Farzaneh F, Mufti G, Tavassoli M and Gaken J: Crucial roles for
protein kinase C isoforms in tumor-specific killing by apoptin.
Cancer Res. 70:7242–7252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Los M, Maddika S, Erb B and
Schulze-Osthoff K: Switching Akt: from survival signaling to deadly
response. Bioessays. 31:492–495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maddika S, Panigrahi S, Wiechec E,
Wesselborg S, Fischer U, Schulze-Osthoff K and Los M: Unscheduled
Akt-triggered activation of cyclin-dependent kinase 2 as a key
effector mechanism of apoptin’s anticancer toxicity. Mol Cell Biol.
29:1235–1248. 2009.PubMed/NCBI
|
|
29
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mo Y, Gan Y, Song S, Johnston J, Xiao X,
Wientjes MG and Au JL: Simultaneous targeting of telomeres and
telomerase as a cancer therapeutic approach. Cancer Res.
63:579–585. 2003.PubMed/NCBI
|
|
31
|
Wirth T, Kuhnel F and Kubicka S:
Telomerase-dependent gene therapy. Curr Mol Med. 5:243–251. 2005.
View Article : Google Scholar
|
|
32
|
Hernandez-Alcoceba R, Pihalja M, Qian D
and Clarke MF: New oncolytic adenoviruses with hypoxia- and
estrogen receptor-regulated replication. Hum Gene Ther.
13:1737–1750. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurihara T, Brough DE, Kovesdi I and Kufe
DW: Selectivity of a replication-competent adenovirus for human
breast carcinoma cells expressing the MUC1 antigen. J Clin Invest.
106:763–771. 2000. View Article : Google Scholar : PubMed/NCBI
|
